Drug Type Small molecule drug |
Synonyms QF 1003B |
Action antagonists |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2B receptor antagonists(Serotonin 2b (5-HT2b) receptor antagonists), D1 receptor antagonists(Dopamine D1 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC20H21FN2O3 |
InChIKeyGQRXUEXACDINRE-UHFFFAOYSA-N |
CAS Registry868855-61-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Schizophrenia | Preclinical | Italy | - | - |
| Schizophrenia | Preclinical | Spain | - | - |





